Want to see FR:ALMDT full AI Analyst Report?
ALMDT Stock Chart & Stats
€4.57
€0.43(9.87%)
At close: 4:00 PM EST
€4.57
€0.43(9.87%)
Day’s Range― - ―
52-Week Range€1.43 - €7.27
Previous CloseN/A
Volume91.16K
Average Volume (3M)465.96K
Market Cap
€233.63M
Enterprise Value€196.06M
Total Cash (Recent Filing)€18.41M
Total Debt (Recent Filing)€21.76M
Price to Earnings (P/E)―
Beta0.53
Next Earnings
Oct 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.15
Shares Outstanding48,659,187
10 Day Avg. Volume398,206
30 Day Avg. Volume465,957
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)-4.95
Price to Sales (P/S)7.45
P/FCF Ratio-9.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.48
Revenue Forecast (FY)€26.53M
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrendRevenue growth of 21.5% in 2025 demonstrates expanding demand for the company's imaging analytics in clinical trials. This growth provides a durable top-line foundation over the next 2–6 months, supporting contract wins and scale efficiencies if cost control follows.
Contracted Services Business ModelA project-based, contracted-services model tied to biopharma trials creates multi-year engagements and recurring revenue opportunities. This aligns cash flows with trial timelines and fosters client stickiness, offering structural demand resilience versus one-off product sales.
Specialized Imaging And AI PositioningDeep specialization in imaging analytics and AI for oncology constitutes a technical and clinical moat requiring validated methods and domain expertise. That specialization supports differentiated services, higher switching costs, and longer-term partnerships with drug developers.
Bears Say
Negative Equity / Weak Balance SheetPersistent negative equity materially reduces financial flexibility and heightens financing and dilution risk. Over a 2–6 month horizon this constrains ability to invest in commercialization or absorb setbacks, making growth plans contingent on external capital or restructuring.
Consistent Negative Operating Cash FlowOngoing negative operating cash flow indicates the business burns cash to fund operations and depends on financing to continue. This undermines self-sufficiency, limits capacity to scale sales and validation activities, and raises execution risk without near-term funding.
Sharp Gross Profit Deterioration And Deep LossesNegative gross profit and large net losses point to structural issues in pricing, cost base, or project economics. Unless gross margins recover, revenue growth will not translate into sustainable earnings, keeping the firm reliant on external funding and limiting long-term viability.
Median Technologies News
ALMDT FAQ
What was Median Technologies’s price range in the past 12 months?
Median Technologies lowest stock price was €1.43 and its highest was €7.27 in the past 12 months.
What is Median Technologies’s market cap?
Median Technologies’s market cap is €233.63M.
When is Median Technologies’s upcoming earnings report date?
Median Technologies’s upcoming earnings report date is Oct 15, 2026 which is in 105 days.
How were Median Technologies’s earnings last quarter?
Median Technologies released its earnings results on Apr 23, 2026. The company reported -€0.677 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.677.
Is Median Technologies overvalued?
According to Wall Street analysts Median Technologies’s price is currently Overvalued.
Does Median Technologies pay dividends?
Median Technologies does not currently pay dividends.
What is Median Technologies’s EPS estimate?
Median Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Median Technologies have?
Median Technologies has 48,659,187 shares outstanding.
What happened to Median Technologies’s price movement after its last earnings report?
Median Technologies reported an EPS of -€0.677 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.957%.
Which hedge fund is a major shareholder of Median Technologies?
Currently, no hedge funds are holding shares in FR:ALMDT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Median Technologies
Headquartered in Valbonne, France, Median Technologies S.A. was established in 2002. This company specializes in developing and commercializing advanced software and platforms designed for medical image analysis. Its reach extends globally, serving markets in France, the United States, Canada, the United Kingdom, China, and beyond. Among its key offerings is iBiops, an innovative, AI-powered software classified as a medical device. This solution comprehensively integrates and optimizes the entire medical imaging workflow. Additionally, Median Technologies provides iSee, a service dedicated to image analysis specifically for clinical trials. Furthermore, the company delivers extensive imaging contract research organization (CRO) services. These encompass a wide range of activities, from study initiation and the management of both image and clinical data, to scientific advisory, independent reviews, image data processing, site support, and final study close-out. Solidifying its commitment to research, Median Technologies maintains a collaborative agreement with the University of California.
Technical Analysis
MAUNA KEA TECHNOLOGIES
―
Theraclion SA
―
Eurobio-Scientific SA
―
Diagnostic Medical Systems
―
Ikonisys SA
―